Increasing prevalence of HIV-1 protease inhibitor-associated mutations correlates with long-term non-suppressive protease inhibitor treatment.
暂无分享,去创建一个
R. Kagan | M. Lewinski | P. Cheung | R M Kagan | P K Cheung | T K Huard | M A Lewinski | T. Huard | Ron M. Kagan
[1] Victoria A Johnson,et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[2] P. Harrigan,et al. Prevalence of primary HIV drug resistance among seroconverters during an explosive outbreak of HIV infection among injecting drug users. , 1999, AIDS.
[3] Valentina Svicher,et al. Novel Human Immunodeficiency Virus Type 1 Protease Mutations Potentially Involved in Resistance to Protease Inhibitors , 2005, Antimicrobial Agents and Chemotherapy.
[4] T. Merigan,et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy , 2000 .
[5] D. Richman,et al. 2022 update of the drug resistance mutations in HIV-1. , 2022, Topics in antiviral medicine.
[6] J. Condra,et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors , 1995, Nature.
[7] Amalio Telenti,et al. Update of the Drug Resistance Mutations in HIV-1: 2005. , 2005, Topics in HIV medicine : a publication of the International AIDS Society, USA.
[8] L J Davis,et al. Active human immunodeficiency virus protease is required for viral infectivity. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[9] Brendan Larder,et al. Interference between D30N and L90M in Selection and Development of Protease Inhibitor-Resistant Human Immunodeficiency Virus Type 1 , 2002, Antimicrobial Agents and Chemotherapy.
[10] Celia A Schiffer,et al. Covariation of amino acid positions in HIV-1 protease. , 2003, Virology.
[11] Rami Kantor,et al. The Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors. , 2000, AIDS reviews.
[12] D. Pillay,et al. Estimating HIV-1 drug resistance in antiretroviral-treated individuals in the United Kingdom. , 2005, The Journal of infectious diseases.
[13] L Hong,et al. Crystal structure of an in vivo HIV‐1 protease mutant in complex with saquinavir: Insights into the mechanisms of drug resistance , 2000, Protein science : a publication of the Protein Society.
[14] P. Harrigan,et al. 2004: which HIV-1 drug resistance mutations are common in clinical practice? , 2004, AIDS reviews.
[15] M. Segal,et al. Evolution of Phenotypic Drug Susceptibility and Viral Replication Capacity during Long-Term Virologic Failure of Protease Inhibitor Therapy in Human Immunodeficiency Virus-Infected Adults , 2002, Journal of Virology.
[16] D. R. Kuritzkes,et al. Genotypic and Phenotypic Characterization of Human Immunodeficiency Virus Type 1 Variants Isolated from Patients Treated with the Protease Inhibitor Nelfinavir , 1998, Antimicrobial Agents and Chemotherapy.
[17] D. Katzenstein,et al. Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapy , 2004, AIDS.
[18] Klaus Korn,et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. , 2005, The Journal of infectious diseases.
[19] Brendan A. Larder,et al. Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples , 2000, AIDS.
[20] B. Ho,et al. Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity , 1989, Journal of virology.
[21] N. Saitou,et al. The neighbor-joining method: a new method for reconstructing phylogenetic trees. , 1987, Molecular biology and evolution.
[22] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .
[23] R. Elston,et al. Emergence of Resistance to Protease Inhibitor Amprenavir in Human Immunodeficiency Virus Type 1-Infected Patients: Selection of Four Alternative Viral Protease Genotypes and Influence of Viral Susceptibility to Coadministered Reverse Transcriptase Nucleoside Inhibitors , 2002, Antimicrobial Agents and Chemotherapy.
[24] W. Heneine,et al. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. , 2004, The Journal of infectious diseases.
[25] F. Ceccherini‐Silberstein,et al. Identification of the minimal conserved structure of HIV-1 protease in the presence and absence of drug pressure , 2004, AIDS.
[26] J. Fantini,et al. Resistance of HIV-1 to multiple antiretroviral drugs in France: a 6-year survey (1997–2002) based on an analysis of over 7000 genotypes , 2003, AIDS.
[27] Thomas D. Wu,et al. Mutation Patterns and Structural Correlates in Human Immunodeficiency Virus Type 1 Protease following Different Protease Inhibitor Treatments , 2003, Journal of Virology.
[28] G. Satten,et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.
[29] L. Bourgon,et al. Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir. , 2005, Antiviral research.
[30] R. Swanstrom,et al. Evolution of Human Immunodeficiency Virus Type 1 Protease Genotypes and Phenotypes In Vivo under Selective Pressure of the Protease Inhibitor Ritonavir , 2005, Journal of Virology.
[31] M. Johnson,et al. Replicative fitness in vivo of HIV‐1 variants with multiple drug resistance‐associated mutations , 2001, Journal of medical virology.
[32] Julio S. G. Montaner,et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. , 2001, JAMA.
[33] J. Martinez-Picado,et al. Replicative Fitness of Protease Inhibitor-Resistant Mutants of Human Immunodeficiency Virus Type 1 , 1999, Journal of Virology.
[34] Christopher J. Lee,et al. Positive Selection Detection in 40,000 HumanImmunodeficiency Virus (HIV) Type 1 Sequences Automatically IdentifiesDrug Resistance and Positive Fitness Mutations in HIV Proteaseand ReverseTranscriptase , 2004, Journal of Virology.
[35] M. Kozal,et al. Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[36] Tommy F. Liu,et al. HIV-1 Protease and reverse-transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance. , 2005, The Journal of infectious diseases.
[37] W. Fitch,et al. Construction of phylogenetic trees. , 1967, Science.
[38] T. Merigan,et al. HIV type 1 genotypic resistance in a clinical database correlates with antiretroviral utilization. , 2004, AIDS research and human retroviruses.